Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2008-05-20
2008-05-20
Shibuya, Mark L. (Department: 1639)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S007100
Reexamination Certificate
active
10357556
ABSTRACT:
The invention provides a method of identifying therapeutic compounds in a genetically defined setting. The method consists of contacting a cell indicative of a pathological condition from a diseased individual and a cell from a genetically related normal individual with a plurality of candidate therapeutic compounds under suitable assay conditions, and identifying a compound that preferentially alters a predetermined property of the cell from the diseased individual.
REFERENCES:
patent: 5134062 (1992-07-01), Blass et al.
patent: 5561047 (1996-10-01), Shattil et al.
patent: 5885776 (1999-03-01), Stone et al.
patent: 5958883 (1999-09-01), Snow
patent: 6087107 (2000-07-01), Sheffield et al.
patent: 6315995 (2001-11-01), Pinsky et al.
patent: 6524797 (2003-02-01), Palsson
patent: WO 90/00619 (1990-01-01), None
patent: WO90/00619 (1990-01-01), None
patent: WO 91/02085 (1991-02-01), None
patent: WO91/02085 (1991-02-01), None
patent: WO 91/15595 (1991-10-01), None
patent: WO91/15595 (1991-10-01), None
patent: WO93/05172 (1993-03-01), None
patent: WO 9305172 (1993-03-01), None
patent: WO94/03602 (1994-02-01), None
patent: WO 94/03602 (1994-02-01), None
patent: WO94/29344 (1994-12-01), None
patent: WO 94/29344 (1994-12-01), None
patent: WO97/19189 (1997-05-01), None
patent: WO 97/19189 (1997-05-01), None
patent: WO97/20064 (1997-06-01), None
patent: WO 97/20064 (1997-06-01), None
patent: WO 97/27212 (1997-07-01), None
patent: WO97/27212 (1997-07-01), None
Bogardus et al., “Pima Indians as a model to study the genetics of NIDDM”J. Cell Biochem.48:337-343 (1992).
Desnottes, J.F., “New targets and strategies for the development of antibacterial agents”TIBTECH14:134-140 (1996).
Francis, G.E., “Theoretical and practical considerations in screening strategies for differentiation agents”Differentiation57:63-75 (1994).
Giuliano and Taylor, “Fluorescent-protein biosensors: new tools for drug discovery”TIBTECH16:135-140 (1998).
Gonzalez and Negulescu, “Intracellular detection assays for high-throughput screening”Curr. Opin. in Biotech9:624-631 (1998).
Gulcher and Stefansson, “Population genomics: laying the groundwork for genetic disease modeling and targeting,”Clin. Chem. Lab. Med.36(8) :523-527 (1998).
Hertzberg, R.P., “Whole cell assays in screening for biologically active substances”Current Opinion in Biotechnology4:80-84 (1993).
Jayawickreme and Kost, “Gene expression systems in the development of high-throughput screens”Curr. Opin. Biotech.8:629-634 (1997).
Major, J., “Challenges of High Throughput Screening Against Cell Surface Receptors”J. Receptor&Signal Transduction Res.15(1-4) :595-607 (1995).
Marshal, E., “Whose DNA Is It, Anyway?”Science278:564-567 (1997).
Perlin et al., “The Plasma Membrane H+-ATPase of Fungi”Annals New York Academy of Sciences834:609-617 (1997).
Persidis, A., “High throughput screening”Nature Biotechnology16:488-489 (1998).
Rice et al., “Development of a High Volume Screen to Identify Inhibitors of Endothelial Cell Activation”Analytical Biochemistry241:254-259 (1996).
Rodrigues, A.D., “Preclinical Drug Metabolism in the Age of High-Throughput Screening: An Industrial Perspective”Pharmaceutical Research14(11) :1504-1510 (1997).
Sheffield et al., “Use of isolated inbred human populations for identification of disease genes”Trends in Genetics14(10) :391-396 (1998).
Smith, D.R., “Microbial pathogen genomes—new strategies for identifying therapeutics and vaccine targets”TIBTECH14:290-293 (1996).
Sterrer and Henco, “Fluorescence Correlation Spectroscopy (FCS)—A Highly Sensitive Method to Analyze Drug-Target Interactions”J. Receptor and Signal Transduction Res.17(1-3) :511-520 (1997).
Sumida et al., “Selective reduction of T cells bearing invariant Vα24JαQ antigen receptor in patients with systemic sclerosis,”J. Exp. Med.182:1163-1168 (1995).
Taylor et al., “Linkage Analysis of Genetic Disorders”Methods Mol. Biol.68:11-25 (1997).
Vuorio et al, “Familial hypercholesterolemia in the Finnish north Karelia. A molecular, clinical, and genealogical study”Arterioscler. Thromb. Vasc. Biol.17:3127-3138 (1997).
Weeks and Lathrop, “Polygenic disease: methods for mapping complex disease traits”Trends in Genetics11(12) :513-519 (1995).
Zamel et al., “Asthma on Tristan de Cunha: looking for the genetic link. The University of Toronto Genetics of Asthma Research Group”Am. J. Respir. Crit. Care Med.153:1902-1906 (1996).
(Visited Dec. 16, 1998) <http://www.aurorabio.com/tech—platform-assay—technologies. html>.
(Visited Dec. 16, 1998) <http://www.aurorabio.com/tech—platform-uhtss—deveopment. html>.
(Visited Dec. 16, 1998) <http://www.mdyn.com/arrays/ArrayImages.html>.
Bogardus et al., “Pima Indians as a model to study the genetics of NIDDM” J. Cell Biochem. 48:337-343 (1992).
Desnottes, J.F., “New targets and strategies for the development of antibacterial agents” TIBTECH 14:134-140 (1996).
Francis, G.E., “Theoretical and practical considerations in screening strategies for differentiation agents” Differentiation 57:63-75 (1994).
Giuliano and Taylor, “Fluorescent-protein biosensors: new tools for drug discovery” TIBTECH 16:135-140 (1998).
Gonzalez and Negulescu, “Intracellular detection assays for high-throughput screening” Curr. Opin. in Biotech 9:624-631 (1998).
Gulcher and Stefansson, “Population Genomics: Laying the Groundwork for Genetic Disease Modeling and Targeting”; Clin Chem Lab Med 1998; 36(i):523-527; 1998 Walter de Gruyter.
Hertzberg, R.P., “Whole cell assays in screening for biologically active substances” Current Opinion in Biotechnology 4:80-84 (1993).
Jayawickreme and Kost, “Gene expression systems in the development of high-throughput screens” Curr. Opin. Biotech. 8:629-634 (1997).
Major, J., “Challenges of High Throughput Screening Against Cell Surface Receptors” J. Receptor & Signal Transduction Res. 15(1-4):595-607 (1995).
Marshal, E., “Whose DNA Is It, Anyway?” Science 278:564-567 (1997).
Perlin et al., “The Plasma Membrane H.sup.+ -ATPase of Fungi” Annals New York Academy of Sciences 834:609-617 (1997).
Persidis, A., “High throughput screening” Nature Biotechnology 16:488-489 (1998).
Rice et al., “Development of a High Volume Screen to Identify Inhibitors of Endothelial Cell Activation” Analytical Biochemistry 241:254-259 (1996).
Rodrigues, A.D., “Preclinical Drug Metabolism in the Age of High-Throughput Screening: An Industrial Perspective” Pharmaceutical Research 14(11):1504-1510 (1997).
Sheffield et al., “Use of isolated inbred human populations for identification of disease genes” Trends in Genetics 14(10):391-396 (1998).
Smith, D.R., “Microbial pathogen genomes—new strategies for identifying therapeutics and vaccine targets” TIBTECH 14:290-293 (1996).
Sterrer and Henco, “Fluorescence Correlation Spectroscopy (FCS)—A Highly Sensitive Method to Analyze Drug-Target Interactions” J. Receptor and Signal Transduction Res. 17(1-3):511-520 (1997).
Sumida et al., “Selective reduction of T cells bearing invariant V.alpha.24J.alpha.Q antigen receptor in patients with systemic sclerosis,” J. Exp. Med. 182:1163-1168 (1995).
Taylor et al., “Linkage Analysis of Genetic Disorders” Methods Mol. Biol. 68:11-25 (1997).
Vuorio et al, “Familial hypercholesterolemia in the Finnish north Karelia. A molecular, clinical, and genealogical study” Arterioscler. Thromb. Vasc. Biol. 17:3127-3138 (1997).
Weeks and Lathrop, “Polygenic disease: methods for mapping complex disease traits” Trends i
McDermott Will & Emery LLP
Palsson Bernhard O
Shibuya Mark L.
LandOfFree
Methods of identifying therapeutic compounds in a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of identifying therapeutic compounds in a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of identifying therapeutic compounds in a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3947101